Tag: progression-free survival
-
Dose Escalation for Somatostatin Analogs in GEP-NETs: Why Higher Doses Could Matter
Understanding the current landscape Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present a range of clinical challenges, from symptom control to tumor progression. Somatostatin analogs (SSAs) such as octreotide LAR and lanreotide are first-line therapies for many patients with metastatic or unresectable GEP-NETs. They help control hormone-related symptoms and often stabilize tumor growth. As trial data accumulate, physicians…
-
Lu-177 PNT2002 Combined with SBRT Delays Prostate Cancer Progression
Overview New data presented at the American Society for Radiation Oncology (ASTRO) meeting suggest that adding the radiopharmaceutical Lu-177 PNT2002 to stereotactic body radiation therapy (SBRT) can significantly delay disease progression in men with oligometastatic, or limited, prostate cancer. The LUNAR trial compared SBRT alone to a two-cycle course of Lu-177 PNT2002 followed by SBRT,…
-
Lu-177 PNT2002 Added to SBRT Delays Prostate Cancer Progression
New approach combines Lu-177 PNT2002 with SBRT In a pioneering study presented at the American Society for Radiation Oncology (ASTRO) meeting, researchers explored whether adding lutetium-177 (Lu-177) PNT2002 to stereotactic body radiation therapy (SBRT) could improve outcomes for men with oligometastatic, or limited, prostate cancer. The strategy targets occult micrometastases that often drive progression after…